Status of Programmed Death Ligand 1 (PD-L1) by Immunohistochemistry and Scoring Algorithms

The detection of the Programmed Death Ligand 1 (PD-L1) protein by immunohistochemistry is currently the only approved test predictive of response to drugs targeting the PD1/PDL1 axis. The role of this test is debated since several reagents have been used as companion diagnostics for different drugs...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Current drug targets Ročník 21; číslo 13; s. 1286
Hlavní autoři: Giunchi, Francesca, Gevaert, Thomas, Scarpelli, Marina, Fiorentino, Michelangelo
Médium: Journal Article
Jazyk:angličtina
Vydáno: United Arab Emirates 01.01.2020
Témata:
PD-L1
algorithms
immunohistochemistry
scoring systems
immunotherapy
Cancer
ISSN:1873-5592, 1873-5592
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The detection of the Programmed Death Ligand 1 (PD-L1) protein by immunohistochemistry is currently the only approved test predictive of response to drugs targeting the PD1/PDL1 axis. The role of this test is debated since several reagents have been used as companion diagnostics for different drugs on diverse immunostaining platforms. In addition, different scoring systems for PD-L1 immunohistochemistry have been applied in the registration studies regarding single drugs. This review deals with the various issues that are related to the immunohistochemical test for PD-L1. We discuss currently unsolved problems such as the advantages and the flaws of PD-L1 immunohistochemistry; the choice of the best reagents and the best scoring system. Finally, we review the current experiences on the role of immunohistochemistry for PD-L1 in clinical trials with immune checkpoint inhibitors.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1873-5592
1873-5592
DOI:10.2174/1389450121666200123124642